Biotechnology Events


BioMarin Pharmaceuticals Inc.




Jean-Jacques Bienaime, Chief Executive Officer, gave guidance for data from the phase-III trial of Pegvaliase for PKU. He stated, "On the development front, in 2015, we achieved a number of important milestones that will drive significant value in 2016 and beyond. Several clinical trials advanced, including the clinical proof-of-concept for reveglucosidase alfa for late onset Pompe disease. We also completed enrollment of our phase-III pivotal trial for Pegvaliase for PKU and are expecting phase-III pivotal data next month."
Source: Q4 2015 earnings conference call, 2/25/16.


Pegvaliase for phenylketonuria (PKU): The Company expects to share top-line results from this study in the first quarter of 2016 and, if the data are supportive, submit a Biologics License Application (BLA) to U.S. FDA in the second half of 2016.
Source: press release, 2/25/16.


Pegvaliase for phenylketonuria (PKU): The Company expects to share top-line results from this study in March/April 2016 and, if the data are supportive, submit a Biologics License Application (BLA) to health authorities in the second half of 2016.
Source: press release, 10/29/15.


Pegvaliase (PEG PAL) for the treatment of phenylketonuria (PKU) is currently in Phase 3 studies. Results are expected in the first quarter of 2016.
Source: press release, 2/25/15.


PRISM-2 - A Four-Part, Phase 3, Randomized, Double-Blind, Placebo- Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self-Administered by Adults With Phenylketonuria (PKU)
Estimated Enrollment: 250
Study Start Date: July 2013
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Source: clinical trials.gvo.


Compound/DeviceSpecialtyIndicationCompound ClassTarget
PEG-PALMedical GeneticsPhenylketonuria (PKU)Enzyme replacement therapyPhenylalanine metabolism

Mechanism of action: PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase or ‘PAL’) is an investigational enzyme substitution therapy for the treatment of severe phenylketonuria (PKU), an inherited metabolic disease caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH).

Phase of Development: III

Event Type: Data: Phase III trial results

Dates: 2016-03-01 - 2016-03-31



BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)
In 8-week Placebo-Controlled Portion No Benefit in Inattention or Mood Scores Were Observed

Approximately, 60% of Patients Maintained Phe Levels At or Below Medical Guidelines
over Long-Term Extension Study

Conference Call and Webcast with Slides to Be Held Today at 8:30 AM ET

SAN RAFAEL, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- BioMarin announced today that the pivotal Phase 3 PRISM-2 study (formerly referred to as 165-302) of pegvaliase met the primary endpoint of change in blood Phe compared with placebo (p<0.0001) in preliminary results. During the 8 week PRISM-2 double-blind, placebo-controlled, randomized drug discontinuation trial (RDT), 86 patients were randomized to either remain on pegvaliase or receive matching placebo. The pegvaliase treated group maintained mean blood Phe levels at 527.2 umol/L compared to their RDT baseline of 503.9 umol/L, whereas the placebo treated group mean blood Phe levels increased to 1385.7 umol/L compared to their RDT baseline of 536.0 umol/L . (see Table 1) The treatment effect demonstrated in this study represents an approximately 62% improvement in blood Phe compared to placebo.

This is the first placebo controlled study demonstrating the ability to improve Phe levels in PKU patients who at baseline do not have to follow a Phe-restricted diet. Typically, a Phe-restricted diet does not allow any protein intake outside of medical food. Patients in the trial were estimated to be eating 75% of the daily recommended allowance for protein intake for a healthy adult.

In the secondary endpoints of the 8 week RDT, no benefit in inattention or mood scores were observed in patients treated with pegvaliase compared to placebo. In an exploratory sub study of cognitive function in 9 patients, the Cambridge Neuropsychological Test Automated Battery (CANTAB) showed trends of improvement favoring pegvaliase. (see Table 2)

In contrast to the short term results of the RDT, supportive evidence of the association of reduced blood Phe and improvement in inattentiveness comes from two long term evaluations in the PRISM-1 and PRISM-2 studies. In these studies, ADHD-RS assessments were obtained prior to treatment and at various times thereafter (scale range 0-27 points, higher score indicating greater impairment). In the open label PRISM-1 study (formerly referred to as 165-301 or feeder study), 49 patients had baseline inattention scores greater than 9 (defining patients with inattentive symptoms at baseline). Of the 35 patients whose Phe was reduced during PRISM-1 by greater than 20%, the mean improvement in inattention was 7.3 points, while the 14 patients whose Phe was reduced by less than 20% only showed an improvement of 3.7. (see Table 3).

In the PRISM-2 study, the 72 patients were evaluated regardless of the baseline scores. Among those who completed 41 weeks in the open-label extension, patients were divided into quartiles based on the magnitude of their Phe reduction from baseline. The quartile of patients having the largest Phe reductions (to values lower than ≥ 1,296 umol/L) had mean improvements in their ADHD-RS inattention score of 7.5 while the patients with the smallest Phe reductions (to values no less than <289 umol/L) had mean improvements in the inattention score of 3.2. (See Table 4).

Practice guidelines issued by the American College of Medical Genetics and Genomics (ACMG) support the need for lifelong management of Phe levels in patients with phenylketonuria or PKU. The guidelines state that the treatment goal for PKU patients should be blood levels of phenylalanine (Phe) for all patients between 120-360 umol/L. The Long Term open label portion of the PRISM-2 study demonstrated sustained and substantial reductions in Phe levels. Of the 90 patients who had been treated for at least 41 weeks in this portion of PRISM-2, 40% had achieved a Phe level of 120 umol/L or less (120 umol/L is considered the upper limit of normal), 60% had achieved a Phe level of 360 umol/L or lower (the target Phe level according to the ACMG guidelines) and 79% had achieved a Phe level reduction of 20% or greater.

PRISM-1 and PRISM-2 studies are the phase 3 studies evaluating blood Phe in PKU patients treated with pegvaliase. PRISM-1 was an open-label study which enrolled and randomized pegvaliase naïve adult PKU patients to a target dose of pegvaliase 20mg/day or 40mg/day. Patients were treated in an induction, titration, maintenance dosing regimen to achieve stable, reduced blood Phe levels. Patients who met a pre-specified reduction in blood Phe of at least 20% (based on two consecutive assessments) from their pre-treatment baseline in the PRISM-1 feeder study were eligible to enter the RDT of the PRISM-2 study, where patients were randomized to continue on their target dose of pegvaliase or to receive matching placebo.

In the PRISM-2 RDT, no subjects discontinued study drug due to adverse events and pegvaliase was generally well tolerated compared to placebo. Pegvaliase treated patients had more hypersensitivity adverse events (39%) as compared to placebo (14%). During the 8 week RDT phase there were no anaphylaxis events as defined by the broad National Institute of Allergy and Infectious Disease and the Food Allergy and Anaphylaxis Network (NIAID/FAAN) (Sampson's) criteria. The most frequent adverse events were arthralgia (pegvaliase 14% vs placebo 10%), headache (pegvaliase 12% vs placebo 24%), fatigue (pegvaliase 11% vs placebo 10%). In the PRISM-2 long term open label extension, the most common adverse events were arthralgia (28%), headache (24%), and injection site reaction (23%).

In PRISM-1, hypersensitivity adverse events and anaphylaxis as defined by the broad NIAID/FAAN criteria were higher during the initial treatment phase and then decreased over time as patients reached stable dosing. Across the entire Phase 3 program, including the PRISM-1 and the PRISM-2 studies, 8% of patients had anaphylaxis by the broad NIAID/FAAN criteria. 48% of patients with anaphylaxis were safely rechallenged and continued dosing with pegvaliase without further anaphylaxis episodes.

The safety data set for all pegvaliase trials includes approximately 550 patient years of treatment, 300 of which are from the Phase 3 program. Approximately 190 patients have been treated with pegvaliase for more than a year, 105 patients have been treated for more than two years and 46 have been treated more than three years.

These studies will be presented at the Society of Inherited Metabolic Disorders in April of 2016.

BioMarin intends to submit a marketing application by the end of the year subject to further discussions with the FDA.

"We are pleased that the double-blind, randomized, placebo-controlled part of the PRISM-2 trial demonstrated strong blood Phe reduction in pegvaliase treated patients whose dietary protein intake was unrestricted at baseline and maintained throughout the study. We are committed to the global PKU community and to bringing them a medicine that has the potential to treat PKU adult patients," said Hank Fuchs, M.D., Chief Medical Officer at BioMarin. "We look forward to sharing this data with the regulatory authorities in the US and Europe to continue the process of bringing an important therapy to patients."

"Treatment with pegvaliase has resulted in dramatic Phe decreases down to within normal levels which have not been achievable in the past with other PKU treatment options. We are grateful to the patients who participated in this important trial. Blood Phe reductions at this level have the potential to have a meaningful impact on the lives of PKU patients," said Cary Harding, M.D. Professor of Molecular and Medical Genetics and Pediatrics at Oregon Health & Science University and investigator for the pegvaliase Phase 3 program.

"A therapy in development that shows such a substantial reduction in Phe levels could mean that for the first time, PKU patients who cannot comply with dietary protein restriction, can achieve targeted blood Phe levels," said Barbara Burton, M.D., Professor of Pediatrics-Genetics, Birth Defects and Metabolism at Northwestern School of Medicine and investigator for the pegvaliase Phase 3 program. "This pegvaliase study represents an important advance for PKU adult patients and a potentially meaningful treatment."

Table 1: Observed Blood Phe Concentration at Treatment Naïve Baseline, Start and End of RDT (mITT Population)

Table 2: Summary of Secondary Efficacy Endpoints in RDT and Efficacy Endpoints in Exploratory Sub
Study of Cognitive Function

Table 3: Change in ADHD-RS Inattention in PRISM 1 and PRISM 2 Part 1 in Subjects with Naïve
Baseline Inattention >9

Table 4: Correlation of Change from Naïve Baseline to Open Label Extension at Week 41
between Blood Phe Concentration and ADHD Inattention Subscale Score in PRISM 2

Phase 3 Study Design

The Phase 3 program consists of two studies. PRISM-1 study was a Phase 3 open-label, randomized, multi-center study that enrolled 261 patients, and its primary objective was to characterize the safety and tolerability of pegvaliase during induction, titration, and maintenance dosing. The secondary objective of the study was to evaluate blood Phe levels during induction, titration, and maintenance dosing to achieve a target dose of pegvaliase 20mg/day or 40mg/day.

215 patients who completed PRISM-1 or PAL-003 (Phase 2 long term extension) enrolled into PRISM-2, which included a randomized, double-blind, placebo-controlled discontinuation study to evaluate the efficacy and safety of subcutaneous injections of pegvaliase self-administered by adults with PKU, followed by an open-label extension. The primary efficacy endpoint is change from the RDT baseline in blood Phe at eight weeks.

Patients who reached a target dose and achieved ≥20% decrease in blood Phe from PRISM-1 baseline were randomized into the RDT portion of the study to either continue their pegvaliase dose or to start matching placebo. Those participants not reaching a ≥20% reduction in blood Phe from PRISM-1 baseline skipped the RDT and enrolled into the open label extension portion of the study. In the open-label extension, physicians were allowed to modify dose based on blood Phe response using a range of doses from 10 mg/day to 60 mg/day. Patients were evaluated for changes in Phe levels and inattention and mood symptoms.
Source: press release, 3/21/16.